Free Newsletter
Report: GlaxoSmithKline in talks to buy India vaccine unit
India's Economic Times is reporting that GlaxoSmithKline Biologicals, a division of GSK, is in talks to acquire Hyderabad-based Biological E's vaccine division. Sources say executives from GSK's Belgium-based unit have visited the India company's manufacturing facility, though talks are preliminary. The India vaccine company makes both pediatric and adult vaccines and possess a sizeable share of India's vaccine market. Its lead products prevent Diphtheria and tetanus.
An unnamed analyst tells the Times that constraints at GSK's plant in Nashik, Maharashtra has caused the company to struggle with its vaccine supply. The BE vaccine unit buyout would give GSK additional capacity in the country. The analyst also observed that the BE's experience with pediatric vaccines would compliment GSK Biologicals' already huge business in that area.
- read the Economic Times report
Related Articles:
GSK's India strategy could come full circle
GSK moves bioprocessing to UK from India
GSK stakes claim in emerging-markets 'land grab'
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: